How Eli Lilly's biotech collaboration model is rewriting early-stage innovation

Описание: Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thomas has spent his career bridging bold discovery science with rigorous development, first in academia and clinical practice, then at Lilly since 2015.


Lilly ExploR&D (https://explornd.lilly.com) represents new thinking in the pharma-biotech collaboration model: a shared-risk, deep scientific partnership designed specifically for early-stage biotechs. It provides full-stack R&D capabilities helping companies overcome the toughest hurdles in moving from molecule creation to clinical proof-of-concept, all while staying lean in a challenging funding environment.


In this episode, Thomas dives into his journey shaping ExploR&D, how the program works in practice, current priorities in modalities and therapeutic areas, and offers some practical advice for biotechs seeking to partner with Eli Lilly.


01:30 — Meet Tom Hopkins


05:11 — What makes ExploR&D biotech-friendly


07:46 — How collaborations work in practice


09:40 — Shared risk models


14:25 — Engaging bold science early


28:16 — Success stories and advice for biotechs


Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?u...)  


Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?...)


To dive deeper into the topic: 

• Eli Lilly’s strategy in motion: Beyond diabetes and obesity (https://www.labiotech.eu/in-depth/eli...)
• Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? (https://www.labiotech.eu/trends-news/...)
• What to look for in a biotech incubator (https://www.labiotech.eu/expert-advic...)